NewsRoom Articles - Page 152 of 207

FridayMay 28, 2021 11:30 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances

Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021 Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and capital markets to draw on in developing its product The company is also working with pharmaceutical partners whose diversity of experience will provide support for Tryp’s path to oral psilocybin development Bio-pharmaceutical…

FridayMay 28, 2021 10:00 am

UM Twin Cities Researchers Find Way to Optimize Immune Response Against Cancer

In what many have described as groundbreaking work, a team of researchers based at University of Minnesota Twin Cities has demonstrated how the body’s immune cells can be engineered in order to navigate the physical barriers that make it hard for an individual’s immune system to fight cancerous tumors. This study has the potential to improve how millions of cancer patients are treated. The research paper was published in the journal “Nature Communications.” Conventionally, cancers are commonly treated through the use of chemicals (chemotherapy), radiation and surgery. Combinations of these approaches are also common. However, immunotherapy is also gaining ground…

FridayMay 28, 2021 9:00 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Highlights, Q1 Financials Herald Bright Horizon for Company

POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises Company subsidiaries reached several milestone achievements throughout the quarter. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, reported its financial results for first quarter 2021, the period ending March 31, 2021 (https://ibn.fm/kUVwH). The company also released key business updates along with its financial numbers. “The combination of equity transactions and retirement of our outstanding debt has brought significant value to…

ThursdayMay 27, 2021 10:48 am

New Microscopic Imaging Method May Help Enhance Bio-Implant Development

Researchers from the University of Birmingham have designed a microscopic imaging approach that may help improve drug screening and disease modeling as well as enhance how bio-implants are developed. 3D-printing platforms are utilized in the development of bio-printed structures using a bio-ink made up of materials, biomolecules and cells, which is passed through a tiny tube. While the method is effective, cells may sometimes get damaged as they are moved through the narrow tube. Through the use of a microscopy technique, the scientists have assessed and found information on how cell damage occurs during the 3D-printing process. The technique, which…

WednesdayMay 26, 2021 11:17 am

Researchers Identify Compound That Could Prevent Drug-Induced Arrhythmias

Some of the most commonly used medications, such as antibiotics, are usually administered in low doses, despite the greater therapeutic benefit they possess, because of the risk of arrhythmias. Arrhythmias occur when an individual’s heartbeat becomes irregular, beating either too slow or too fast. Cardiac arrhythmias usually occur when electrical impulses in an individual’s heart aren’t working properly. A team of researchers from various institutions have discovered a compound that hinders cardiac arrhythmias from occurring when these drugs are given in higher doses, through experimental and computational validation. This will make it easier for these drugs to be administered safely,…

WednesdayMay 26, 2021 9:00 am

Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio

Company files 12th patent to strengthen proprietary IP program Cybin believes treatments can decrease costs, increase access to important therapeutics Patent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding its four active drug programs targeting depression, addiction and other psychiatric conditions alongside its growing portfolio of 50+ proprietary psychedelic molecules. “By continuing to innovate in directions to enhance the patient experience and…

TuesdayMay 25, 2021 1:08 pm

Case Study Shows Coronavirus Infection Can Trigger Recurrent Blood Clots

Rutgers Robert Wood Johnson Medical School researchers have discovered that the coronavirus may cause blood clots in an individual’s arms. Their findings, which were reported in the “Viruses” journal, delve into how inflammation brought about by the coronavirus can result in upper extremity blood clots. This case study is part of a bigger study by the institution involving a group of patients that had contracted the coronavirus infection and were either discharged or admitted to a hospital between March and May of last year. While researchers do know that the disease may cause lower extremity deep vein thrombosis, this is…

TuesdayMay 25, 2021 10:30 am

GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial

Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (“GBM”) brain cancer patients GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once they are diagnosed, prompting research efforts to improve patients’ responses to therapeutic approaches A recent study found that the GBM patients most likely to succumb within a relatively short period could be identified with non-invasive MRI scans, allowing researchers to grant them priority in clinical trials Another recent study found patient responses could be improved simply by changing the time of…

TuesdayMay 25, 2021 10:13 am

Brain Scientific Inc. (BRSF) May Provide Diagnostics Solutions for Sports Concussions as They Become Growing Public Health Problem

Sports concussions on the rise; with more children playing sports, it is becoming an important public health problem Quantitative EEG shows promise in identifying athletes with post-concussion impairments; for this, reusable EEG caps and mobile-based applications are helpful BRSF provides portable EEG devices that bring brain diagnostics to settings where it was previously impossible including off-site testing within sports A recent article published by Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company operating in the brain diagnostics space, discusses how concussions or Traumatic brain injuries (“TBI”) are a significant risk for young athletes, quickly becoming an important public health issue…

MondayMay 24, 2021 1:51 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida The idea…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances

UM Twin Cities Researchers Find Way to Optimize Immune Response Against Cancer

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Highlights, Q1 Financials Herald Bright Horizon for Company

New Microscopic Imaging Method May Help Enhance Bio-Implant Development

Researchers Identify Compound That Could Prevent Drug-Induced Arrhythmias

Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio

Case Study Shows Coronavirus Infection Can Trigger Recurrent Blood Clots

GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial

Brain Scientific Inc. (BRSF) May Provide Diagnostics Solutions for Sports Concussions as They Become Growing Public Health Problem

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search